Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
950260.KQ
Strong SellSinkerIngenia Therapeutics Inc. · Healthcare · United States · $649M
7
StockRankGet insider-trade alerts
Q
26
V
25
M
25
P/E (TTM)
—
ROE
—
D/E
—
Dividend %
—
COMPANY DESCRIPTION
Ingenia Therapeutics Inc. operates as a clinical-stage antibody biopharmaceutical company that discovers and develops biopharmaceutical candidates based on microvascular protection and recovery technology in the United States and South Korea.
Loading 1Y...
PRICE (1Y)-12.8%
Close
$11.92
RSI (14)
54.0
SCORE BREAKDOWN
Quality
26
ROIC (ROA)
—N/A
ROE
—N/A
GP/Assets
—N/A
Op. Margin
0.0%38.1
FCF/Assets
—N/A
Piotroski
0N/A
Int. Cover
—N/A
D/E Ratio
—N/A
Current Ratio
—N/A
Value
25
P/E (TTM)
—N/A
EV/EBITDA
—N/A
P/FCF
—N/A
P/B
—N/A
P/S
—N/A
Div Yield
—N/A
Momentum
25
52W High %
—N/A
RS 6M
—N/A
SMA 50/200
—N/A
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$649M
P/E (Forward)
—
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 950260.KQ are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 950260.KQ | Ingenia Therapeutics Inc.(you) | $649M | 7 | Strong Sell |
| RGNX | REGENXBIO Inc. | $638M | 8 | Strong Sell |
| SPRY | ARS Pharmaceuticals, Inc. | $586M | 6 | Strong Sell |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | $701M | 8 | Strong Sell |
| BLSM | BlossomHill Therapeutics, Inc. | $569M | 7 | Strong Sell |
| EIKN | Eikon Therapeutics, Inc. | $595M | 10 | Strong Sell |
| ALLO | Allogene Therapeutics, Inc. | $698M | 10 | Strong Sell |
| KYTX | Kyverna Therapeutics, Inc. | $518M | 7 | Strong Sell |
| PROK | ProKidney Corp. | $731M | 4 | Strong Sell |
| PRME | Prime Medicine, Inc. | $655M | 2 | Strong Sell |
Peer medians: ROE -30.7% · P/E 27.0x · Gross margin 58.3%